You are here

  • Home
  • Archive
  • Volume 6, Issue 1
  • Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations

Article metrics

Article menu

Download PDFPDF

Research Article
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations

 

Online download statistics by month:

Online download statistics by month: December 2019 to March 2026

AbstractFullPdf
Dec 2019771
Jan 202021210
Feb 2020515114
Mar 2020707125
Apr 2020484827
May 2020767635
Jun 2020464614
Jul 2020666625
Aug 2020474730
Sep 2020575719
Oct 2020949431
Nov 2020676719
Dec 2020797929
Jan 2021939346
Feb 2021737329
Mar 2021848429
Apr 2021898965
May 2021787850
Jun 2021595930
Jul 2021545431
Aug 2021717153
Sep 2021636345
Oct 2021676757
Nov 2021727251
Dec 2021616236
Jan 2022647339
Feb 2022667737
Mar 2022656635
Apr 2022707729
May 2022686837
Jun 2022555530
Jul 2022646723
Aug 20229910225
Sep 2022677219
Oct 2022778847
Nov 2022686935
Dec 2022343416
Jan 2023929228
Feb 2023777726
Mar 202310410427
Apr 2023656539
May 2023576031
Jun 2023494917
Jul 2023555732
Aug 2023525228
Sep 2023454520
Oct 2023535324
Nov 2023474918
Dec 2023666629
Jan 2024787934
Feb 2024495022
Mar 2024474732
Apr 2024555629
May 2024363619
Jun 2024403922
Jul 2024565714
Aug 2024444316
Sep 2024414213
Oct 2024414125
Nov 2024717237
Dec 2024656629
Jan 2025676735
Feb 202529629642
Mar 202512512517
Apr 2025777721
May 2025595940
Jun 2025373719
Jul 2025110
Feb 2026110
Mar 2026220
Total444045051948